Article
St. Louis-When faced with a patient who presents with the uncommon symptoms of facial numbness and pain, John B. Selhorst, MD, underscored their importance because of the potential for serious outcomes.
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial